A citation-based method for searching scientific literature

Kasper Fugger, Graeme Hewitt, Stephen C West, Simon J Boulton. Trends Cancer 2021
Times Cited: 3







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
66

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
66

Targeting the replication stress response in cancer.
Josep V Forment, Mark J O'Connor. Pharmacol Ther 2018
79
33

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Rinske Drost, Kiranjit K Dhillon, Hanneke van der Gulden, Ingrid van der Heijden, Inger Brandsma, Cristina Cruz, Dafni Chondronasiou, Marta Castroviejo-Bermejo, Ute Boon, Eva Schut,[...]. J Clin Invest 2016
76
33

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris-Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán,[...]. EMBO Mol Med 2018
95
33

Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.
Katharina Schlacher, Nicole Christ, Nicolas Siaud, Akinori Egashira, Hong Wu, Maria Jasin. Cell 2011
743
33

A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency.
Liu Cao, Xioaling Xu, Samuel F Bunting, Jie Liu, Rui-Hong Wang, Longyue L Cao, J Julie Wu, Tie-Nan Peng, Junjie Chen, Andre Nussenzweig,[...]. Mol Cell 2009
221
33

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Stephanie A Yazinski, Valentine Comaills, Rémi Buisson, Marie-Michelle Genois, Hai Dang Nguyen, Chu Kwen Ho, Tanya Todorova Kwan, Robert Morris, Sam Lauffer, André Nussenzweig,[...]. Genes Dev 2017
191
33

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Yong Fang, Daniel J McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P Vellano, Yiling Lu, Yongsheng Li,[...]. Cancer Cell 2019
86
33

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Andrew N J Tutt, Judy E Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña,[...]. N Engl J Med 2021
120
33

The plasticity of DNA replication forks in response to clinically relevant genotoxic stress.
Matteo Berti, David Cortez, Massimo Lopes. Nat Rev Mol Cell Biol 2020
60
33

Dual roles of PARP-1 promote cancer growth and progression.
Matthew J Schiewer, Jonathan F Goodwin, Sumin Han, J Chad Brenner, Michael A Augello, Jeffry L Dean, Fengzhi Liu, Jamie L Planck, Preethi Ravindranathan, Arul M Chinnaiyan,[...]. Cancer Discov 2012
241
33

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Triparna Sen, B Leticia Rodriguez, Limo Chen, Carminia M Della Corte, Naoto Morikawa, Junya Fujimoto, Sandra Cristea, Thuyen Nguyen, Lixia Diao, Lerong Li,[...]. Cancer Discov 2019
276
33

53BP1: a DSB escort.
Zachary Mirman, Titia de Lange. Genes Dev 2020
82
33

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, Anna V Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L Coleman, Howard A Burris, Carol Aghajanian, David M O'Malley,[...]. Gynecol Oncol 2021
1
100


Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
994
33

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
Yifan Wang, John J Krais, Andrea J Bernhardy, Emmanuelle Nicolas, Kathy Q Cai, Maria I Harrell, Hyoung H Kim, Erin George, Elizabeth M Swisher, Fiona Simpkins,[...]. J Clin Invest 2016
51
33

Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Likun Li, Styliani Karanika, Guang Yang, Jiangxiang Wang, Sanghee Park, Bradley M Broom, Ganiraju C Manyam, Wenhui Wu, Yong Luo, Spyridon Basourakos,[...]. Sci Signal 2017
102
33


Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
A G Waks, O Cohen, B Kochupurakkal, D Kim, C E Dunn, J Buendia Buendia, S Wander, K Helvie, M R Lloyd, L Marini,[...]. Ann Oncol 2020
53
33

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Nuala McCabe, Nicholas C Turner, Christopher J Lord, Katarzyna Kluzek, Aneta Bialkowska, Sally Swift, Sabrina Giavara, Mark J O'Connor, Andrew N Tutt, Małgorzata Z Zdzienicka,[...]. Cancer Res 2006
865
33

Unlocking the potential of antibody-drug conjugates for cancer therapy.
Joshua Z Drago, Shanu Modi, Sarat Chandarlapaty. Nat Rev Clin Oncol 2021
95
33

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Diana Zatreanu, Helen M R Robinson, Omar Alkhatib, Marie Boursier, Harry Finch, Lerin Geo, Diego Grande, Vera Grinkevich, Robert A Heald, Sophie Langdon,[...]. Nat Commun 2021
24
33

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Neil Johnson, Shawn F Johnson, Wei Yao, Yu-Chen Li, Young-Eun Choi, Andrea J Bernhardy, Yifan Wang, Marzia Capelletti, Kristopher A Sarosiek, Lisa A Moreau,[...]. Proc Natl Acad Sci U S A 2013
161
33

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
810
33

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.
Janneke E Jaspers, Wendy Sol, Ariena Kersbergen, Andreas Schlicker, Charlotte Guyader, Guotai Xu, Lodewyk Wessels, Piet Borst, Jos Jonkers, Sven Rottenberg. Cancer Res 2015
31
33

BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
Dali Zong, Salomé Adam, Yifan Wang, Hiroyuki Sasanuma, Elsa Callén, Matilde Murga, Amanda Day, Michael J Kruhlak, Nancy Wong, Meagan Munro,[...]. Mol Cell 2019
52
33

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
Liliana D Ordonez, Trevor Hay, Robert McEwen, Urszula M Polanska, Adina Hughes, Oona Delpuech, Elaine Cadogan, Steve Powell, Jonathan Dry, Giusy Tornillo,[...]. Oncotarget 2019
9
33

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
Claudia Winkler, Joshua Armenia, Gemma N Jones, Luis Tobalina, Matthew J Sale, Tudor Petreus, Tarrion Baird, Violeta Serra, Anderson T Wang, Alan Lau,[...]. Br J Cancer 2021
17
33

Detection of functional protein domains by unbiased genome-wide forward genetic screening.
Mareike Herzog, Fabio Puddu, Julia Coates, Nicola Geisler, Josep V Forment, Stephen P Jackson. Sci Rep 2018
8
33

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
H P Eikesdal, S Yndestad, A Elzawahry, A Llop-Guevara, B Gilje, E S Blix, H Espelid, S Lundgren, J Geisler, G Vagstad,[...]. Ann Oncol 2021
30
33

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, Y H Ibrahim, A Gris-Oliver, S Bonache, B Morancho, A Bruna, O M Rueda,[...]. Ann Oncol 2018
153
33

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
978
33

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Olga Kondrashova, Minh Nguyen, Kristy Shield-Artin, Anna V Tinker, Nelson N H Teng, Maria I Harrell, Michael J Kuiper, Gwo-Yaw Ho, Holly Barker, Maria Jasin,[...]. Cancer Discov 2017
174
33

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Zsofia K Stadler, Erin Salo-Mullen, Sujata M Patil, M Catherine Pietanza, Joseph Vijai, Emmanouil Saloustros, Nichole A L Hansen, Noah D Kauff, Robert C Kurtz, David P Kelsen,[...]. Cancer 2012
68
33

BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.
Samuel F Bunting, Elsa Callén, Marina L Kozak, Jung Min Kim, Nancy Wong, Andrés J López-Contreras, Thomas Ludwig, Richard Baer, Robert B Faryabi, Amy Malhowski,[...]. Mol Cell 2012
200
33

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Hyoung Kim, Haineng Xu, Erin George, Dorothy Hallberg, Sushil Kumar, Veena Jagannathan, Sergey Medvedev, Yasuto Kinose, Kyle Devins, Priyanka Verma,[...]. Nat Commun 2020
59
33

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke, Gwo-Yaw Ho, Maria I Harrell, Giada V Zapparoli, Alison Hadley, Robert Holian, Emma Boehm,[...]. Nat Commun 2018
97
33

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
Ashish Juvekar, Laura N Burga, Hai Hu, Elaine P Lunsford, Yasir H Ibrahim, Judith Balmañà, Anbazhagan Rajendran, Antonella Papa, Katherine Spencer, Costas A Lyssiotis,[...]. Cancer Discov 2012
293
33

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Yifan Wang, Andrea J Bernhardy, Cristina Cruz, John J Krais, Joseph Nacson, Emmanuelle Nicolas, Suraj Peri, Hanneke van der Gulden, Ingrid van der Heijden, Shane W O'Brien,[...]. Cancer Res 2016
130
33

Resistance to therapy caused by intragenic deletion in BRCA2.
Stacey L Edwards, Rachel Brough, Christopher J Lord, Rachael Natrajan, Radost Vatcheva, Douglas A Levine, Jeff Boyd, Jorge S Reis-Filho, Alan Ashworth. Nature 2008
680
33

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
Praveen Vikas, Nicholas Borcherding, Adithya Chennamadhavuni, Rohan Garje. Front Oncol 2020
54
33

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.
Stephen J Pettitt, Farah L Rehman, Ilirjana Bajrami, Rachel Brough, Fredrik Wallberg, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Lina Chen, James Campbell,[...]. PLoS One 2013
113
33

BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
Yifan Wang, Andrea J Bernhardy, Joseph Nacson, John J Krais, Yin-Fei Tan, Emmanuelle Nicolas, Marc R Radke, Elizabeth Handorf, Alba Llop-Guevara, Judith Balmaña,[...]. Nat Commun 2019
22
33

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
650
33

Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.
Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M Kass, Maria Jasin. Annu Rev Cancer Biol 2018
112
33

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
517
33

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
33

53BP1 Enforces Distinct Pre- and Post-resection Blocks on Homologous Recombination.
Elsa Callen, Dali Zong, Wei Wu, Nancy Wong, Andre Stanlie, Momoko Ishikawa, Raphael Pavani, Lavinia C Dumitrache, Andrea K Byrum, Carlos Mendez-Dorantes,[...]. Mol Cell 2020
52
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.